Landos Biopharma
(NASDAQ) LABP
Landos Biopharma Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$0.00
Net Income (TTM)
$24.80M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
LABP News
LABP: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Landos Biopharma
Industry
Pharmaceuticals
Sector
Health CareEmployees
19
CEO
Gregory Oakes, MBA
Website
www.landosbiopharma.comHeadquarters
Blacksburg, VA 24060, US
LABP Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-62%
Return on Capital
-71%
Return on Assets
-58%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$22.73M
EBITDA
$22.68M
Operating Cash Flow
$20.48M
Capital Expenditure
$0.00
Free Cash Flow
$20.48M
Cash & ST Invst.
$37.55M
Total Debt
$0.00
Landos Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$0.00
N/A
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
19
N/A
Net Income
$8.90M
-59.2%
EBITDA
$9.25M
-42.9%
Quarterly Fundamentals
Net Cash
$29.05M
-41.9%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$0.00
N/A
Short Term Debt
$0.00
N/A
Return on Assets
-57.66%
N/A
Return on Invested Capital
-71.49%
N/A
Free Cash Flow
$8.50M
-4.0%
Operating Cash Flow
$8.50M
-4.0%